2026 Q1 -tulosraportti
22 päivää sitten
‧43 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 25 | CAR | NON | ||
| 75 | NON | NON | ||
| 50 | CAR | NON | ||
| 350 | NON | NON | ||
| 48 | NON | NON |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 27.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
·2 päivää sittenI don't really think it will get past 21kr 🫣
·19 t sittenI think it needs to go under 15kr again And then it's time to trade again I think that 233% increase for me = sale Irrelevant that it had passed 24.8 which is the second resistance and the psychological barrier 25kr is a sales figure for the big boys so it needs big news again. Let's hope the money could possibly be saved through a collaboration like cessatech succeeded with Rigshospitalet, so a lot of dilution is saved I think an emission is coming around August
·15 t sittenCompletely agree, there is some expectation priced into the stock price at the moment, but not close to the potential. If data is strong as we hope and believe, the current price is very, very cheap. That's also why I believe the price can rise considerably as we approach Topline. And after strong data, it can become really interesting.
·3 päivää sittenSell recommendation?
·3 päivää sittenAre you crazy? I am not selling a single one. Maybe one should buy up and secure an early retirement. 🫡😎
·3 päivää sittenhttps://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2024-520105-39-00 uTREAT phase 1: hmm...has the page not been updated with the following information: Estimated end of trial date in EU/EEA: 23/07/2026 Then we might potentially get topline data end of July / beginning of August... ?
·3 päivää sitten · MuokattuThe Clinical trail dokumentet has been updated via an SM (Substantial Modification). Curasight sent the SM on 27-02-2026 and it was approved on 24-03-2026 (as stated on the front page, cf.. your link) The only thing that has been changed is the Estimated end of trial date in EU/EEA. It has been changed from 15-05-2026 to 27-07-2026. They have thus moved the end date for the GBM Phase I study by a good 2 months. This is due to the expansion of the study from 60 Gy to 100+ Gy and the number of patients from 6 to 12. The first time we heard about the expansion was on 26-02-2026 at the HCA meeting in connection with the annual report (to my knowledge). Here they show a slide describing the expansions and the guided Topline-results mid- 2026. The day after, they send an SM and then guide read-out in Q2 and Topline in Q3. I will not place too much emphasis on the Estimated end of trial date in relation to when Topline results will actually come, as the date is in no way binding! But it gives an indication of what they believed back ultimo Feb. As previously mentioned, I believe mid/ultimo July, especially because they published read-out data 3 weeks before the deadline. And it is a relatively small cohort, so 6-8 weeks should be sufficient for topline data. And it is somewhat in the same direction as they themselves might have had in mind.....but now we have to see. Data is King - we need to see it! ⚡
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
22 päivää sitten
‧43 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·2 päivää sittenI don't really think it will get past 21kr 🫣·19 t sittenI think it needs to go under 15kr again And then it's time to trade again I think that 233% increase for me = sale Irrelevant that it had passed 24.8 which is the second resistance and the psychological barrier 25kr is a sales figure for the big boys so it needs big news again. Let's hope the money could possibly be saved through a collaboration like cessatech succeeded with Rigshospitalet, so a lot of dilution is saved I think an emission is coming around August·15 t sittenCompletely agree, there is some expectation priced into the stock price at the moment, but not close to the potential. If data is strong as we hope and believe, the current price is very, very cheap. That's also why I believe the price can rise considerably as we approach Topline. And after strong data, it can become really interesting.
- ·3 päivää sittenSell recommendation?·3 päivää sittenAre you crazy? I am not selling a single one. Maybe one should buy up and secure an early retirement. 🫡😎
- ·3 päivää sittenhttps://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2024-520105-39-00 uTREAT phase 1: hmm...has the page not been updated with the following information: Estimated end of trial date in EU/EEA: 23/07/2026 Then we might potentially get topline data end of July / beginning of August... ?·3 päivää sitten · MuokattuThe Clinical trail dokumentet has been updated via an SM (Substantial Modification). Curasight sent the SM on 27-02-2026 and it was approved on 24-03-2026 (as stated on the front page, cf.. your link) The only thing that has been changed is the Estimated end of trial date in EU/EEA. It has been changed from 15-05-2026 to 27-07-2026. They have thus moved the end date for the GBM Phase I study by a good 2 months. This is due to the expansion of the study from 60 Gy to 100+ Gy and the number of patients from 6 to 12. The first time we heard about the expansion was on 26-02-2026 at the HCA meeting in connection with the annual report (to my knowledge). Here they show a slide describing the expansions and the guided Topline-results mid- 2026. The day after, they send an SM and then guide read-out in Q2 and Topline in Q3. I will not place too much emphasis on the Estimated end of trial date in relation to when Topline results will actually come, as the date is in no way binding! But it gives an indication of what they believed back ultimo Feb. As previously mentioned, I believe mid/ultimo July, especially because they published read-out data 3 weeks before the deadline. And it is a relatively small cohort, so 6-8 weeks should be sufficient for topline data. And it is somewhat in the same direction as they themselves might have had in mind.....but now we have to see. Data is King - we need to see it! ⚡
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 25 | CAR | NON | ||
| 75 | NON | NON | ||
| 50 | CAR | NON | ||
| 350 | NON | NON | ||
| 48 | NON | NON |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 27.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 |
2026 Q1 -tulosraportti
22 päivää sitten
‧43 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 27.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·2 päivää sittenI don't really think it will get past 21kr 🫣·19 t sittenI think it needs to go under 15kr again And then it's time to trade again I think that 233% increase for me = sale Irrelevant that it had passed 24.8 which is the second resistance and the psychological barrier 25kr is a sales figure for the big boys so it needs big news again. Let's hope the money could possibly be saved through a collaboration like cessatech succeeded with Rigshospitalet, so a lot of dilution is saved I think an emission is coming around August·15 t sittenCompletely agree, there is some expectation priced into the stock price at the moment, but not close to the potential. If data is strong as we hope and believe, the current price is very, very cheap. That's also why I believe the price can rise considerably as we approach Topline. And after strong data, it can become really interesting.
- ·3 päivää sittenSell recommendation?·3 päivää sittenAre you crazy? I am not selling a single one. Maybe one should buy up and secure an early retirement. 🫡😎
- ·3 päivää sittenhttps://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2024-520105-39-00 uTREAT phase 1: hmm...has the page not been updated with the following information: Estimated end of trial date in EU/EEA: 23/07/2026 Then we might potentially get topline data end of July / beginning of August... ?·3 päivää sitten · MuokattuThe Clinical trail dokumentet has been updated via an SM (Substantial Modification). Curasight sent the SM on 27-02-2026 and it was approved on 24-03-2026 (as stated on the front page, cf.. your link) The only thing that has been changed is the Estimated end of trial date in EU/EEA. It has been changed from 15-05-2026 to 27-07-2026. They have thus moved the end date for the GBM Phase I study by a good 2 months. This is due to the expansion of the study from 60 Gy to 100+ Gy and the number of patients from 6 to 12. The first time we heard about the expansion was on 26-02-2026 at the HCA meeting in connection with the annual report (to my knowledge). Here they show a slide describing the expansions and the guided Topline-results mid- 2026. The day after, they send an SM and then guide read-out in Q2 and Topline in Q3. I will not place too much emphasis on the Estimated end of trial date in relation to when Topline results will actually come, as the date is in no way binding! But it gives an indication of what they believed back ultimo Feb. As previously mentioned, I believe mid/ultimo July, especially because they published read-out data 3 weeks before the deadline. And it is a relatively small cohort, so 6-8 weeks should be sufficient for topline data. And it is somewhat in the same direction as they themselves might have had in mind.....but now we have to see. Data is King - we need to see it! ⚡
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 25 | CAR | NON | ||
| 75 | NON | NON | ||
| 50 | CAR | NON | ||
| 350 | NON | NON | ||
| 48 | NON | NON |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt